Positron emission tomography In assessing response to neoadjuvant chemotherapy for non‐small‐cell lung cancer

Dm, Thomas; Pl, Mitchell; Su, B; Tochon-Danguy, Henri; Knight, Simon; Cp, Clarke; Scott, Andrew M.

doi:10.5694/j.1326-5377.1998.tb140229.x

Cited by 10 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 22 patients with advanced breast cancer, changes in FDG uptake were able to predict the eventual histopathologic response with an accuracy of 88% after the first course of drugs and 91% after the second course [ 76 ]. Similar utility has been described in cancers of the lung [ 77 ] and colon [ 78 ], as well as Hodgkin's [ 79 ] and non-Hodgkin's lymphoma [ 80 ].…”

Section: Imagingmentioning

confidence: 55%

Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation

2007

View full text Add to dashboard Cite

show abstract

Section: Imagingmentioning

confidence: 55%

Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation

2007

View full text Add to dashboard Cite

show abstract

“…6). 2,7,14,46 The timing and reliability of 18 F-FDG PET studies in predicting tumour response are the subjects of numerous prospective studies at present. The implications of this approach are significant in terms of optimizing treatment regimens, minimizing unnecessary morbidity and reducing costs.…”

Section: Monitoring Response Of Tumour To Therapymentioning

confidence: 99%

Current status of positron emission tomography in oncology

Scott

2002

Australasian Radiology

View full text Add to dashboard Cite

Positron emission tomography (PET) has emerged as a powerful diagnostic tool in oncology patients. There is evidence of the superior utility over conventional imaging methods of the principal PET tracer 18F-fluoro-2-deoxy-glucose in the staging of a range of cancers and monitoring disease recurrence, as well as changing patient management to more appropriate therapy. The methods for evaluating the evidence for PET remain complex, particularly as the standard evidence-based approach of randomized controlled trials is not generally applicable to imaging technologies. PET has the potential to dramatically improve our ability to manage patients with cancer and is also making major contributions to the development of new therapies.

show abstract

“…6). 2,7,14,46 The timing and reliability of 18 F‐FDG PET studies in predicting tumour response are the subjects of numerous prospective studies at present. The implications of this approach are significant in terms of optimizing treatment regimens, minimizing unnecessary morbidity and reducing costs.…”

Section: Monitoring Response Of Tumour To Therapymentioning

confidence: 99%

Current status of positron emission tomography in oncology

Scott

2001

Internal Medicine Journal

View full text Add to dashboard Cite

Positron emission tomography (PET) has emerged as a powerful diagnostic tool in oncology patients. There is evidence of the superior utility over conventional imaging methods of the principal PET tracer 18 Ffluoro-2-deoxy-glucose in the staging of a range of cancers and monitoring disease recurrence, as well as changing patient management to more appropriate therapy. The methods for evaluating the evidence for PET remain complex, particularly as the standard evidence-based approach of randomized controlled trials is not generally applicable to imaging technologies. PET has the potential to dramatically improve our ability to manage patients with cancer and is also making major contributions to the development of new therapies. (Intern Med J 2000; 31: 27-36)

show abstract

Positron emission tomography In assessing response to neoadjuvant chemotherapy for non‐small‐cell lung cancer

Cited by 10 publications

References 4 publications

Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation

Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation

Current status of positron emission tomography in oncology

Current status of positron emission tomography in oncology

Contact Info

Product

Resources

About